Choisissez une région:


Logo de la CCSIR. Logo de la faculté de la médecine de l'université d'Ottawa.
Logo de Bruyere

Global Refugees Checklist
© CCSIR 2013 Tous droits réservés

Apperçu du VIH

Needs to be translated.

Immigrants and refugees from countries with high prevalence of HIV (>1%) are vulnerable because of the high HIV prevalence in their home countries and because of high levels of HIV-related stigma that often persists in their Canadian communities.  Refugees and refugee claimants may delay testing and/or treatment because of lack of knowledge of effective treatments, or because they fear failing to obtain legal immigration status if HIV-positive:

Key Recommendations:

*> 1% HIV = sub-Saharan Africa, Caribbean, Thailand

Quality of Evidence: MODERATE

Balance of benefits and harms Values and preferences
  • Prevalence of HIV infection is higher among immigrants from countries where HIV is prevalent (> 1%) than among other Canadians (< 0.18%).
  • The decision to screen men and women for HIV is based on a dramatic reduction in mortality with treatment, e.g., with a combination of three versus two antiretrovirals (NNT 132, 95% CI 91–357) and reduction of high-risk behaviour (NNT 5, 95% CI 4–7).
  • Harms included adverse drug reactions requiring change in regimen.
  • Data on harms related to anxiety and possible discrimination related to HIV status are unavailable.

The committee attributed more value to:

  • Identifying HIV-positive women and men for appropriate treatment, support and prevention

Attributed less value to:

  • Uncertain risk of couple discord and risk of discrimination
  • Burden of testing with informed consent

Links to Other Learning Resources

K. Pottie, C. Greenaway, J. Feightner et autres. « Evidence-based clinical guidelines for immigrants and refugees », JAMC, 2011. DOI 10.1503/cmaj.090313.

Conception et production : Centre du cyber-@pprentissage, Service d'appui à l'enseignement et à l'apprentissage (SAEA), Université d'Ottawa